AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05689229
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Trial: NCT05785624
Drug: Vixarelimab
RxNorm normalized name: Vixarelimab
DrugBank: Vixarelimab (DB16350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.
Trial: NCT04847544
Drug: ADX-629
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX-629 administered orally twice daily (BID) for up to 28 days.
Trial: NCT05121740
Drug: Plitidepsin 1.5 mg / day
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
Trial: NCT05121740
Drug: Plitidepsin 2.0 mg / day
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
Trial: NCT05121740
Drug: Plitidepsin 2.5 mg / day
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
Trial: NCT06796803
Drug: camrelizumab combined with rivoceranib and HAIC
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic therapy combined with locoregional theraphy as conversion therapy
Trial: NCT06796803
Drug: camerlizumab + rivoceranib
RxNorm normalized name: Lambrolizumab
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic therapy
Trial: NCT06643832
Drug: Lidocaine (drug)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine will be used by mixing it with the propofol before intravenous injection
Trial: NCT04704661
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06291376
Drug: Ravulizumab
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
Trial: NCT06471686
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 pills three times a day
Trial: NCT04716634
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
Trial: NCT04716634
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
Trial: NCT06793670
Drug: Landiolol
RxNorm normalized name: Landiolol
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion of landiolol
Trial: NCT06793371
Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CK-4021586 administered orally
Trial: NCT06276556
Drug: ABP-671
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.
Trial: NCT06276556
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Trial: NCT05384015
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance).
Trial: NCT05384015
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion
Trial: NCT05384015
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles
Trial: NCT05384015
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles
Trial: NCT06125587
Drug: Chiglitazar
RxNorm normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
Trial: NCT06125587
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Trial: NCT05048134
Drug: HRS2300、trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HRS2300 combined with trametinib
Trial: NCT05048134
Drug: HRS2300、Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS2300 combined with Almonertinib
Trial: NCT05640830
Drug: trastuzumab, bevacizumab with paclitaxel (triple combination)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
Trial: NCT06466122
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06466122
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06363994
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
Trial: NCT06363994
Drug: Bendamustine Injection
RxNorm normalized name: bendamustine Injection
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive Bendamustine by injection as per the protocol
Trial: NCT06363994
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will receive Rituximab by injection as per the protocol
Trial: NCT06363994
Drug: Orelabrutinib Placebo
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
Trial: NCT06157892
Drug: disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenous)
Trial: NCT06157892
Drug: tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg given twice daily by mouth (orally)
Trial: NCT04730609
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
Trial: NCT06284343
Drug: Anticoagulant
RxNorm normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
Trial: NCT05083923
Drug: Diroximel fumarate
RxNorm normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT06108414
Drug: low-dose rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Trial: NCT06108414
Drug: Standard-dose rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Trial: NCT03454750
Drug: 177Lu-PSMA
RxNorm normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
Trial: NCT04749628
Drug: cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex (cannabidiol) oral solution
Trial: NCT06340347
Drug: Osivelotor
RxNorm normalized name: Osivelotor
DrugBank: Osivelotor (DB18071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367
Trial: NCT05473195
Drug: Ethionamide 250mg
RxNorm normalized name: ETHIONAMIDE 250MG TAB
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide 250 mg po OD (Eto250)
Trial: NCT05473195
Drug: Ethionamide 250 mg
RxNorm normalized name: ethionamide 250 MG
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide 750 mg po given in a single or divided dose (Eto750)
Trial: NCT05473195
Drug: Isoniazid 300 MG
RxNorm normalized name: isoniazid 300 MG
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg po OD (INH)
Trial: NCT04822337
Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
Trial: NCT04637763
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for lymphodepletion
Trial: NCT04929249
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Trial: NCT05471479
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal
Trial: NCT05824832
Drug: Interscalene block with the addition of buprenorphine, clonidine, dexamethasone
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
Trial: NCT05824832
Drug: Interscalene block with buprenorphine alone
RxNorm normalized name: Ivy Block
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
Trial: NCT05153915
Drug: Tacrolimus granules
RxNorm normalized name: tacrolimus Granules for Oral Suspension
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05252754
Drug: Tacrolimus capsule
RxNorm normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
Trial: NCT05610774
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
Trial: NCT05610774
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
Trial: NCT05888493
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
Trial: NCT05888493
Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
Trial: NCT05888493
Drug: Lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)
Trial: NCT05029882
Drug: ABBV-400
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT05029882
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT04944992
Drug: Efinopegdutide 20 mg/mL
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
Trial: NCT04944992
Drug: Semaglutide 1.34 mg/mL
RxNorm normalized name: semaglutide 1.34 MG/ML
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
Trial: NCT05757141
Drug: Fosigotifator
RxNorm normalized name: Fosigotifator
DrugBank: Fosigotifator (DB19409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Use
Trial: NCT06233240
Drug: Sitagliptin and Metformin Hydrochloride Tablets Test product
RxNorm normalized name: metformin and sitagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
Trial: NCT06233240
Drug: Sitagliptin and Metformin Hydrochloride Tablets Reference product
RxNorm normalized name: metformin and sitagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Trial: NCT05007613
Drug: Cabozantinib 40 MG
RxNorm normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib (Cabometyx) 40 MG PO QD
Trial: NCT05007613
Drug: Atezolizumab Injection
RxNorm normalized name: atezolizumab Injection
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
Trial: NCT03902951
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03902951
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03902951
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT05400317
Drug: AD-218
RxNorm normalized name: Freon 218
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 12weeks
Trial: NCT06245564
Drug: Ketamine 0.5%
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
Trial: NCT06245564
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
Trial: NCT06245564
Drug: ketamine + amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
Trial: NCT05854667
Drug: Treatment as Usual plus lisdexamfetamine (LDX-01)
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15).
Trial: NCT05854667
Drug: Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management
RxNorm normalized name: hydrocortisone 0.01 MG/MG [Hemorrodil Plus]
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13.
Trial: NCT06191991
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg
Trial: NCT06160843
Drug: Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
Trial: NCT04665765
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04665765
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04665765
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV